par Stamatakos, Georgios;Dionysiou, Dimitra;Graf, Norbert;Sofra, Nikoletta N.A.;Desmedt, Christine 
;Hoppe, Alexander;Uzunoglu, Nikolaos N.K.;Tsiknakis, Manolis
Référence Proceedings of the annual Conference on Engineering in Medicine and Biology, page (6628-6631), 4353879
Publication Publié, 2007
;Hoppe, Alexander;Uzunoglu, Nikolaos N.K.;Tsiknakis, ManolisRéférence Proceedings of the annual Conference on Engineering in Medicine and Biology, page (6628-6631), 4353879
Publication Publié, 2007
Article révisé par les pairs
| Résumé : | The "Oncosimulator" is at the same time a concept of multilevel integrative cancer and (treatment affected) normal tissue biology, an algorithmic construct and a software tool which aims at supporting the clinician in the process of optimizing cancer treatment on the patient individualized basis. Additionally it is a platform for better understanding and exploring the natural phenomenon of cancer as well as training doctors and interested patients alike. In order to achieve all of these goals it has to undergo a thorough clinical optimization and validation process. This is one of the goals of the European Commission funded integrated project "ACGT: Advancing Clinicogenomic Trials on Cancer". Nephroblastoma (Wilms' tumor) and breast cancer have been selected to serve as two paradigms to clinically specify and evaluate the "Oncosimulator" as well as the emerging domain of in silico oncology. ©2007 IEEE. |
